Compounded semaglutide reaches patients through one of two regulated pharmacy pathways under the U.S. Federal Food, Drug, and Cosmetic Act: Section 503A licensed compounding pharmacies and Section 503B FDA-registered outsourcing facilities.
Section 503A: licensed by state pharmacy boards. Compounds based on patient-specific prescriptions. Operates under USP <797> sterile compounding standards. Bulk compounding for office use is restricted. Section 503B: registered with FDA. Operates under FDA cGMP standards (21 CFR 211). Permitted to compound in larger volumes for distribution to facilities without patient-specific prescriptions. NexLife uses both pathways and discloses both publicly. Many competitors disclose neither.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.